DNA methylation profiling of non-small cell lung cancer reveals a COPD-driven immune-related signature

Thorax

Volumn 70, Issue 12, 2015, Pages 1113-1122

  Wauters, Els ^a,b,c   Janssens, Wim ^c   Vansteenkiste, Johan ^c   Decaluwé, Herbert ^c   Heulens, Nele ^a   Thienpont, Bernard ^a,b   Zhao, Hui ^a,b   Smeets, Dominiek ^a,b   Sagaert, Xavier ^a   Coolen, Johan ^c   Decramer, Marc ^c   Liston, Adrian ^a   De Leyn, Paul ^c   Moisse, Matthieu ^a,b   Lambrechts, Diether ^a,b  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; DNA;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GENETICS; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DNA METHYLATION; FEMALE; GENE EXPRESSION; GENE ONTOLOGY; GENOME ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOPATHOGENESIS; LUNG EMPHYSEMA; LUNG PARENCHYMA; MALE; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; PROSPECTIVE STUDY; SMOKING; TRANSCRIPTOMICS; CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; IMMUNOLOGY; LUNG NEOPLASMS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

CARCINOMA, NON-SMALL-CELL LUNG; COMORBIDITY; DNA METHYLATION; HUMANS; LUNG NEOPLASMS; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 84957851166     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thoraxjnl-2015-207288     Document Type: Article

References (35)

1. Booton R, Blackhall F, Kerr K. Individualised treatment in non-small cell lung cancer: precise tissue diagnosis for all? Thorax 2011;66:273-5.
2. Heyn H, Esteller M. DNA methylation profiling in the clinic: applications and challenges. Nat Rev Genet 2012;13:679-92.
3. Dedeurwaerder S, Desmedt C, Calonne E, et al. DNA methylation profiling reveals a predominant immune component in breast cancers. EMBO Mol Med 2011;3:726-41.
4. Young RP, Hopkins RJ, Christmas T, et al. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. Eur Respir J 2009;34:380-6.
5. Mannino DM, Aguayo SM, Petty TL, et al. Low lung function and incident lung cancer in the United States: data From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003;163:1475-80.
6. Lambrechts D, Buysschaert I, Zanen P, et al. The 15q24/25 susceptibility variant for lung cancer and chronic obstructive pulmonary disease is associated with emphysema. Am J Respir Crit Care Med 2010;181:486-93.
7. Wauters E, Smeets D, Coolen J, et al. The TERT-CLPTM1L locus for lung cancer predisposes to bronchial obstruction and emphysema. Eur Respir J 2011;38:924-31.
8. Houghton AM. Mechanistic links between COPD and lung cancer. Nat Rev Cancer 2013;13:233-45.
9. Vucic EA, Chari R, Thu KL, et al. DNA methylation is globally disrupted and associated with expression changes in chronic obstructive pulmonary disease small airways. Am J Respir Cell Mol Biol 2014;50:912-22.
10. Christensen BC, Houseman EA, Marsit CJ, et al. Aging and environmental exposures alter tissue-specific DNA methylation dependent upon CpG island context. PLoS Genet 2009;5:e1000602.
11. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-46.
12. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-55.
13. Houseman EA, Christensen BC, Yeh RF, et al. Model-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising as a mixture of beta distributions. BMC Bioinform 2008;9:365.
14. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Statist Soc 1995;57:289-300.
15. Easwaran H, Johnstone SE, Van Neste L, et al. A DNA hypermethylation module for the stem/progenitor cell signature of cancer. Genome Res 2012;22:837-49.
16. Ku M, Koche RP, Rheinbay E, et al. Genomewide analysis of PRC1 and PRC2 occupancy identifies two classes of bivalent domains. PLoS Genet 2008;4:e1000242.
17. Benoist C, Lanier L, Merad M, et al. Consortium biology in immunology: the perspective from the Immunological Genome Project. Nat Rev Immunol 2012;12:734-40.
18. van den Berge M, Steiling K, Timens W, et al. Airway gene expression in COPD is dynamic with inhaled corticosteroid treatment and reflects biological pathways associated with disease activity. Thorax 2014;69:14-23.
19. Weinstein JN, Collisson EA, Mills GB, et al. The Cancer Genome Atlas Pan-Cancer analysis project. Nat Genet 2013;45:1113-20.
20. Tangye SG, Ma CS, Brink R, et al. The good, the bad and the ugly - TFH cells in human health and disease. Nat Rev Immunol 2013;13:412-26.
21. Bhattacharya S, Srisuma S, Demeo DL, et al. Molecular biomarkers for quantitative and discrete COPD phenotypes. Am J Respir Cell Mol Biol 2009;40:359-67.
22. Lamontagne M, Timens W, Hao K, et al. Genetic regulation of gene expression in the lung identifies CST3 and CD22 as potential causal genes for airflow obstruction. Thorax 2014;69:997-1004.
23. Yoo S, Takikawa S, Geraghty P, et al. Integrative analysis of DNA methylation and gene expression data identifies EPAS1 as a key regulator of COPD. PLoS Genet 2015;11:e1004898.
24. Sato T, Arai E, Kohno T, et al. Epigenetic clustering of lung adenocarcinomas based on DNA methylation profiles in adjacent lung tissue: its correlation with smoking history and chronic obstructive pulmonary disease. Int J Cancer 2014;135:319-34.
25. Kim WJ, Lim JH, Lee JS, et al. Comprehensive analysis of transcriptome sequencing data in the lung tissues of COPD subjects. Int J Genomics 2015;2015:206937.
26. Wang IM, Stepaniants S, Boie Y, et al. Gene expression profiling in patients with chronic obstructive pulmonary disease and lung cancer. Am J Respir Crit Care Med 2008;177:402-11.
27. Brusselle GG, Joos GF, Bracke KR. New insights into the immunology of chronic obstructive pulmonary disease. Lancet 2011;378:1015-26.
28. Berenson CS, Kruzel RL, Eberhardt E, et al. Impaired innate immune alveolar macrophage response and the predilection for COPD exacerbations. Thorax 2014;69:811-18.
29. Dancer R, Sansom DM. Regulatory T cells and COPD. Thorax 2013;68:1176-8.
30. Hou J, Sun Y, Hao Y, et al. Imbalance between subpopulations of regulatory T cells in COPD. Thorax 2013;68:1131-9.
31. Budinska E, Popovici V, Tejpar S, et al. Gene expression patterns unveil a new level of molecular heterogeneity in colorectal cancer. J Pathol 2013;231:63-76.
32. Tan TZ, Miow QH, Huang RY, et al. Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med 2013;5:983-98.
33. Ignatiadis M, Singhal SK, Desmedt C, et al. Gene modules and response to neoadjuvant chemotherapy in breast cancer subtypes: a pooled analysis. J Clin Oncol 2012;30:1996-2004.
34. Rizvi NA, Mazieres J, Planchard D, et al. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncol 2015;16:257-65.
35. Wan ES, Qiu W, Baccarelli A, et al. Systemic steroid exposure is associated with differential methylation in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:1248-55.